Antisense restenosis composition and method
AssigneeAVI BioPharma, Inc.
InventorsPatrick L. Iversen, Dwight D. Weller
Life of this patent
Estimating the term…
Abstract
The present invention provides an improved method for reducing the risk or severity of restenosis following cardiac angioplasty. The method includes administering to a target vessel region, a morpholino antisense compound having uncharged phosphorus-containing backbone linkages, and spanning the start codon of a human c-myc mRNA. Also disclosed are novel antisense compounds and compositions, and a method for assaying the effectiveness of antisense delivery and uptake to a target vessel region.
Claims13
A method for treating a vascular injury site in a human patient by reducing restenosis at the site, said method comprising:
- administering to the patient, by intravascular delivery directly to the vascular injury site, a morpholino antisense compound having uncharged phosphorodiamidate intersubunit linkages of the form:
- where X═N(CH3)2, Y═O, Z═O, and Pi and Pj are independently selected from adenine, guanine, cytosine, thymine and uracil;
- and comprising the sequence identified as SEQ ID NO:1, in an amount effective to reduce restenosis in the patient.
A method for treating a vascular injury site in a human patient, said method comprising:
- providing an intravascular stent wherein said stent or a coating on said stent contains a morpholino antisense compound in diffusible form, wherein the morpholino antisense compound has uncharged phosphorodiamidate intersubunit linkages of the form:
- where X═N(CH3)2, Y═O, and Z═O, and Pi and Pj are independently selected from adenine, guanine, cytosine, thymine and uracil;
- and comprises the sequence identified as SEQ ID NO:
- 1, and
- contacting the vascular injury site with said stent, effective to administer said compound to the patient, in an amount effective to reduce restenosis in the patient.
Dependencies are inferred from the claim text.